Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study.
Saved in:
| Title: | Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study. |
|---|---|
| Authors: | Muñoz-Barba D; Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.; Dermatology Department, School of Medicine, University of Granada, Granada, Spain., García-Moronta C; Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.; Dermatology Department, School of Medicine, University of Granada, Granada, Spain., Haselgruber-de Francisco S; Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.; Dermatology Department, School of Medicine, University of Granada, Granada, Spain., Sánchez-Díaz M; Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.; Dermatology Department, School of Medicine, University of Granada, Granada, Spain.; Institute of Biosanitary Research IBS, Granada, Spain., Arias-Santiago S; Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain.; Dermatology Department, School of Medicine, University of Granada, Granada, Spain.; Institute of Biosanitary Research IBS, Granada, Spain.; Trichology Clinic, Hospital Universitario Virgen de las Nieves, Granada, Spain. |
| Source: | The Journal of dermatological treatment [J Dermatolog Treat] 2025 Dec; Vol. 36 (1), pp. 2583877. Date of Electronic Publication: 2025 Nov 24. |
| Publication Type: | Journal Article; Observational Study |
| Language: | English |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : Informa Healthcare Original Publication: Houndmills, Basingstoke, Hampshire, UK : M. Dunitz and Macmillan Press, [c1989]- |
| MeSH Terms: | Alopecia Areata*/drug therapy , Alopecia Areata*/diagnosis , Azetidines*/adverse effects , Azetidines*/therapeutic use , Azetidines*/administration & dosage , Sulfonamides*/adverse effects , Sulfonamides*/therapeutic use , Sulfonamides*/administration & dosage , Pyrazoles*/adverse effects , Pyrazoles*/therapeutic use, Humans ; Purines/adverse effects ; Female ; Male ; Prospective Studies ; Adult ; Middle Aged ; Treatment Outcome ; Severity of Illness Index ; Young Adult ; Follow-Up Studies |
| Abstract: | Background and Objectives: Baricitinib was effective in treating severe alopecia areata (AA) in clinical trials, yet real-world prospective data remain scarce. The aim of this study was to assess real-world effectiveness and safety of Baricitinib. Patients and Methods: A prospective observational study was conducted including 48 adults with severe AA over a 12-month follow-up. Clinical response, laboratory data, and adverse events were assessed. Predictors of response were also explored. The primary endpoint was defined as the attainment of a Severity of Alopecia Tool (SALT) score <20%, sustained over at least two consecutive assessments separated by ≥12 weeks within the first year of therapy. Results: A clinically meaningful response (SALT <20) was achieved by 58.3% of patients and 37.5% achieved a complete response (SALT <10). Early responders represented 29.5% of the cohort. Eyebrow and eyelash regrowth improved ( p < 0.01). Predictors of favorable response included lower baseline SALT, shorter disease duration, and higher basal erythrocyte sedimentation rate (ESR). No serious adverse events were reported. Conclusions: Baricitinib is effective and safe in the real-world management of severe AA, especially when initiated early in patients with lower baseline severity and elevated ESR. These findings highlight the relevance of timely intervention and appropriate patient selection. |
| Contributed Indexing: | Keywords: Alopecia areata; Baricitinib; Janus kinase inhibitors; hair |
| Substance Nomenclature: | ISP4442I3Y (baricitinib) 0 (Purines) 0 (Azetidines) 0 (Sulfonamides) 0 (Pyrazoles) |
| Entry Date(s): | Date Created: 20251124 Date Completed: 20251124 Latest Revision: 20251124 |
| Update Code: | 20251124 |
| DOI: | 10.1080/09546634.2025.2583877 |
| PMID: | 41277365 |
| Database: | MEDLINE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Background and Objectives: Baricitinib was effective in treating severe alopecia areata (AA) in clinical trials, yet real-world prospective data remain scarce. The aim of this study was to assess real-world effectiveness and safety of Baricitinib.<br />Patients and Methods: A prospective observational study was conducted including 48 adults with severe AA over a 12-month follow-up. Clinical response, laboratory data, and adverse events were assessed. Predictors of response were also explored. The primary endpoint was defined as the attainment of a Severity of Alopecia Tool (SALT) score <20%, sustained over at least two consecutive assessments separated by ≥12 weeks within the first year of therapy.<br />Results: A clinically meaningful response (SALT <20) was achieved by 58.3% of patients and 37.5% achieved a complete response (SALT <10). Early responders represented 29.5% of the cohort. Eyebrow and eyelash regrowth improved ( p < 0.01). Predictors of favorable response included lower baseline SALT, shorter disease duration, and higher basal erythrocyte sedimentation rate (ESR). No serious adverse events were reported.<br />Conclusions: Baricitinib is effective and safe in the real-world management of severe AA, especially when initiated early in patients with lower baseline severity and elevated ESR. These findings highlight the relevance of timely intervention and appropriate patient selection. |
|---|---|
| ISSN: | 1471-1753 |
| DOI: | 10.1080/09546634.2025.2583877 |